Acquisitions10 Sept 2025, 11:29 am
NATCO Pharma to Acquire Minority Shares in Adcock Ingram for $228 Million
AI Summary
NATCO Pharma Limited, a Hyderabad-based pharmaceutical company, has submitted a firm intention cash offer of ZAR 75 per share to Adcock Ingram to acquire the minority-held shares. This will amount to an acquisition cost of around ZAR 4 billion or $228 million at the current prevailing exchange rate. Upon approval and fulfillment of conditions, Adcock Ingram will be delisted by 11 November 2025.
Key Highlights
- NATCO Pharma to acquire minority shares in Adcock Ingram for $228 million
- Adcock Ingram to be delisted from the JSE upon acquisition
- NATCO Pharma and Bidvest to seek new revenue streams and opportunities in the African market
- Adcock Ingram is a leading South African pharmaceutical company with a wide range of products
- NATCO Pharma is a diversified pharmaceutical manufacturer with a focus on research, development, and global marketing